期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 9, 期 8, 页码 991-1003出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590903055029
关键词
CpG; cystic fibrosis; lipopolyplexes; liposomes; lung disease; non-viral gene therapy; plasmid DNA; polymers
Gene therapy has been proposed for a wide range of human diseases but few have received the level of attention over such a prolonged period as cystic fibrosis (CF) with over 20 clinical studies undertaken. Following a 10-year interval, clinical trials of an aerosolisable non-viral gene transfer agent have recently been initiated by researchers in the United Kingdom. Here we review the rationale and requirements for effective gene therapy for CF lung disease. The previous non-viral gene therapy trials are discussed and the prospects for the current leading non-viral formulations for CF gene therapy are considered. Factors affecting the selection and design of the plasmid DNA molecule, likely to be of central importance to clinical efficacy are reviewed and we describe the potential merits of the formulation that has been selected for the forthcoming UK trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据